Abstract

The Extended Spectrum Beta-Lactamases (ESBLs) producing bacteria is an issue of concern for clinicians resulting in minimize the treatment options. To overcome resistance mechanisms, novel inhibitors with good Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties must inhibit the ESBLs resistant genes. The current study aimed to identify the antibiotic resistance genes of ESBLs producing E. coli and a single inhibitor was designed to inhibit all the resistant proteins. The results showed that 42.9% ESBL producers had CTX-M (69.9%), TEM (63.4%), SHV (34.5%) and CTX-M-14 (17.5%) genes. The ESBLs producing isolates were resistant to cephalosporins, quinolones, and sulfonamide with Minimum Inhibitory Concentration (MICs) ranging from 64 to >256 μg/ml. To design multi inhibitory ligands, RECAP synthesis was used for the de-novo discovery of 1000 inhibitors database. Protein crystal structures were retrieved from Protein Data Base (PDB). Lipinski’s rules of five were applied to the novel inhibitors database to improve the ADMET properties. The novel inhibitors database was selected for docking simulations. Placement of the ligand was used by the London dG algorithm implemented in Molecular Operating Environment (MOE), while GBVI/WSA dG algorithm was used for final refinement. Based on docking score, visual inspection of ligands interaction with key residues, binding affinity, and binding energy of ligands with proteins, ten compounds were selected for ESBLs proteins with best ADMET properties, binding energy, and binding affinity the reported ones. These hits compounds have unique scaffolds and are predicted to be a starting point for developing potent inhibitors against antibiotic-resistant proteins.

Highlights

  • Escherichia coli are Gram-negative bacilli belong to Enterobacteriaceae, commonly present in the human gut

  • The majority of the Extended Spectrum Beta-Lactamases (ESBLs)-Ec isolates were recovered from urine 151 (61.4%) followed by pus 72(29.3%)

  • The results of the different clinical isolates of ESBLs-Ec revealed that 151(61.4%) patients had Urinary Tract Infections (UTIs), 87(35.3%) patients had Severe Systemic Infections (SSIs), while 08(3.3%) patients had severe Pulmonary Infections (PIs)

Read more

Summary

Introduction

Escherichia coli are Gram-negative bacilli belong to Enterobacteriaceae, commonly present in the human gut. The most common diseases caused by E. coli are; Urinary Tract Infections (UTIs) (Foxman, 2010), enteric infections, bacteremia, nosocomial pneumonia, cholecystitis, cholangitis, peritonitis, cellulitis, osteomyelitis, infectious arthritis, and neonatal meningitis (Kim, 2012). These infections are commonly treated with antibiotics, but improper use of these antibiotics has developed resistance in E. coli strains resulting in severe health issues worldwide (El Kholy et al, 2003).

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call